According to Zhitong Finance App News, Yao Ming Biotech (02269) announced its 2026 interim results. The group achieved revenue of 11.787 billion yuan, up 18.4% year on year; gross profit of 5.448 billion yuan, up 28.1% year on year; net profit due to company owners of 2.44 billion yuan, up 4.3% year on year; company owners should account for adjusted net profit of 3.306 billion yuan, up 38.4% year on year; basic profit per share.

According to the announcement, revenue growth reflects the Group's overall growth in various project stages and regional markets, mainly due to strong demand for new IND enablement projects, continuous advancement of multiple projects to late-stage clinical development and commercial production, and steady growth in the North American market.

The Group's integrated end-to-end CRDMO platform and “follow and win” strategy continued to drive steady growth in the project portfolio during the reporting period. As of June 30, 2026, the Group added a total of 169 comprehensive projects, bringing the total number of comprehensive projects to 1,064, of which the number of post-clinical and commercial production projects increased to 78 and 28, respectively. The Group also obtained 16 external projects through the “Win Molecules” strategy during the reporting period, including 4 post-clinical projects and 1 commercial production project, to provide further impetus for future growth.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.